Effect of heparin on production of transforming growth factor (TGF)-β1 and TGF-β1 mRNA expression by human normal skin and hyperplastic scar fibroblasts

Annals of Plastic Surgery

Volumn 60, Issue 3, 2008, Pages 299-305

  Fan, Shu Qiang ^a   Cai, Jing Long ^b   Qin, Li Yan ^c   Wang, Zhi Hong ^a   Liu, Zhen Zhong ^b   Sun, Ming Liang ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

^c SHANDONG JIAOTONG UNIVERSITY   (China)

Author keywords

Heparin; Hyperplastic scar; Transforming growth factor 1; Transforming growth factor 1 mRNA

Indexed keywords

COMPLEMENTARY DNA; FIBRINOLYTIC AGENT; HEPARIN; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; BIOSYNTHESIS; BURN; CELL PROLIFERATION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST; GENETICS; HUMAN; HYPERTROPHIC SCAR; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN;

BURNS; CELL PROLIFERATION; CICATRIX, HYPERTROPHIC; DNA, COMPLEMENTARY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FIBRINOLYTIC AGENTS; FIBROBLASTS; HEPARIN; HUMANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SKIN; TRANSFORMING GROWTH FACTOR BETA1;

EID: 44849091937     PISSN: 01487043     EISSN: 15363708     Source Type: Journal    
DOI: 10.1097/SAP.0b013e318061d310     Document Type: Article

References (53)

1. Cavari S, Ruggiero M, Vannucchi S. Antiproliferative effects of heparin on normal and transformed NIH/3T3 fibroblasts. Cell Biol Int. 1993;17:781-786.
2. Ferrao AV, Mason RM. The effect of heparin on cell proliferation and type-I collagen synthesis by adult human dermal fibroblasts. Biochim Biophys Acta. 1993;1180:225-230.
3. San Antonio JD, Lander AD, Wright TC, et al. Heparin inhibits the attachment and growth of Balb/c-3T3 fibroblasts on collagen substrata. J Cell Physiol. 1992;150:8 -16.
4. Striker LJ, Peten EP, Elliot SJ, et al. Mesangial cell turnover: effect of heparin and peptide growth factors. Lab Invest. 1991;64:446-456.
5. Wever J, Schachtschabel DO, Sluke G, et al. Effect of short- or long-term treatment with exogenous glycosaminoglycans on growth and glycosaminoglycan synthesis of human fibroblasts (WI-38) in culture. Mech Ageing Dev. 1980;14:89 -99.
6. Asselot C, Labat-Robert J, Kern P. Heparin fragments regulate collagen phenotype and fibronectin synthesis in the skin of genetically diabetic mice. Biochem Pharmacol. 1989;38:895- 899.
7. el Nabout R, Martin M, Remy J, et al. Heparin fragments modulate the collagen phenotype of fibroblasts from radiation-induced subcutaneous fibrosis. Exp Mol Pathol. 1989;51:111-122.
8. Tan EM, Peltonen J. Endothelial cell growth factor and heparin regulate collagen gene expression in keloid fibroblasts. Biochem J. 1991;278(Pt 3):863- 869.
9. Assagué J. The transforming growth factor-β family. Annu Rev Cell Biol. 1990;6:597.
10. Border WA, Noble NA. Transforming growth factor β in tissue fibrosis. N Engl J Med. 1994;331:1286.
11. Miyazono K, ten Dijke P, Heldin CH. TGF-β signaling by Smad proteins. Adv Immunol. 2000;75:115.
12. Robson MC. The role of growth factors in the healing of chronic wounds. Wound Repair Regen. 1997;5:12-17.
13. Hong RH, Lum J, Koch RJ. Growth of keloid-producing fibroblasts in commercially available serum-free media. Otolaryngol Head Neck Surg. 1999;121:468-473.
14. Castellot JJ, Addonizio ML, Rosenberg RD, et al. Cultured endothelial cells produce a heparin-like inhibitor of smooth muscle cell growth. J Cell Bio1. 1981;90:372-379.
15. Reilly CF, Fritze LMS, Rosenberg RD. Heparin inhibition of smooth muscle cell proliferation: a cellular site of action. J Cell Physiol. 1986;129:11-19.
16. Vannuchi S, Pasquali F, Fiorelli G, et al. Effect of heparin on proliferation and signalling in BC3H-1 muscle cells. FEBS Lett. 1990;263:137-141.
17. Herbert JM, Maffrund JP. Heparin interactions with cultured human vascular endothelial and smooth muscle cells: incidence on vascular smooth muscle proliferation. J Cell Physiol. 1989;138:424-432.
18. Vannuchi S, Pasquali F, Chiarugi V, et al. Internalization and metabolism of endogenous heparin by cultured endothelial cells. Biochem Biophys Res Commun. 1986;140:294 -301.
19. Schaffrath D, Stahlsatz HW, Greiling H. Interactions of glycosaminoglycans with DNA and RNA synthesizing enzymes in vitro. Hoppe Seylers Z Physiol Chem. 1976;357:499 -508.
20. Kitamura M, Maruyama N, Mitarai T, et al. Heparin selectively inhibits gene expression of matrix metalloproteinase transin in cultured mesangial cells. Biochem Biophys Res Commun. 1994;203:1333-1338.
21. Gosh TK, Eis PS, Mullaney JM, et al. Competitive, reversible, and potent antagonism of inositol 1,4,5-triphosphate-activated calcium release by heparin. J Biol Chem. 1988;263:11075-11079.
22. Smith CD, Wen D, Mooberry SL, et al. Inhibition of phosphatidylinositol- 4-phosphate by heparin. Biochem J. 1990;109:441- 448.
23. Bennett MR, Littlewood TL, Hancock DC, et al. Down-regulation of the c-myc proto-oncogene in inhibition of vascular smooth-muscle cell proliferation: a signal for growth arrest? Biochem J. 1994;302: 701-708.
24. Pukac LA, Castellot JJ, Wright TC, et al. Heparin inhibits c-fos and c-myc mRNA expression in vascular smooth muscle cells. J Biol Chem. 1992;267:3707-3711.
25. Reilly CR, Kindy MS, Brown KE, et al. Heparin prevents vascular smooth muscle progression through the G1 phase of the cell cycle. J Biol Chem. 1989;264:6990-6995.
26. Wright RC, Pukac LA, Catellot JJ, et al. Heparin suppresses the induction of c-fos and c-myc mRNA in murine fibroblasts by selective inhibition of a protein kinase c-dependent pathway. Proc Natl Acad Sci U S A. 1989;86:3199 -3203.
27. Yamada KM, Kennedy DW, Kimata K, et al. Characterization of fibronectin interactions with glycosaminoglycans and identification of active proteolytic fragments. J Biol Chem. 1980;255:6055- 6063.
28. Sakashita S, Engvall E, Ruoslahti E. Basement membrane glycoprotein laminin binds to heparin. FEBS Lett. 1980;116:243-246.
29. Lawler J, Slayter H. The release of heparin binding peptides from platelet thrombospondin by proteolytic action of thrombin, plasmin, and trypsin. Thromb Res. 1981;22:267-279.
30. Keller KM, Keller JM, Kuhn K. The c-terminus of type I collagen is a major binding site for heparin. Biochim Biophys Acta. 1986;882:1-5.
31. Tsilibary EC, Reger LA, Vogel AM, et al. Identification of a multifunctional, cell-binding peptide sequence from the a1(NC1) of type IV collagen. J Cell Biol. 1990;111:1583-1591.
32. Younai S, Nichter LS, Wellisz T, et al. Modulation of collagen synthesis by transforming growth factor-beta in keloid and hypertrophic scar fibroblasts. Ann Plast Surg. 1994;33:148 -151.
33. Grassel S, Tan EM, Timpl R, et al. Collagen type XVI expression is modulated by basic fibroblast growth factor and transforming growth factor-beta. FEBS Lett. 1998;436:197-201.
34. Ignotz RA, Massague J. Regulation of fibronectin and type I collagen mRNA levels by transforming growth factor-beta. J Biol Chem. 1987; 262:6443- 6447.
35. Peltonen J, Kahari L, Jaakkola S. Evaluation of transforming growth factor-beta and type I procollagen gene expression in fibrotic skin diseases by in situ hybridization. J Invest Dermatol. 1990;94:365- 371.
36. Varga J, Rosenbloom J, Jimenez SA. Transforming growth factor beta (TGF-beta) causes a persistent increase in steady-state amounts of type I and type III collagen and fibronectin mRNAs in normal human dermal fibroblasts. Biochem J. 1987;247:597- 604.
37. Moulin V. Growth factors in skin wound healing. Eur J Cell Biol. 1995;68:1-7.
38. Kissin EY, Lemarie R, Korn JH, et al. Transforming growth factor beta induces fibroblast fibrillin-1 matrix formation. Arthritis Rheum. 2002; 46:3000 -3009.
39. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med. 1994;331:1286 -1292.
40. Andres JL, Stanley K, Cheifetz S, et al. Membrane-anchored and soluble forms of betaglycan, a polymorphic proteoglycan that bind transforming growth factor-beta. J Cell Biol. 1989;109:3137-3145.
41. Cheifetz S, Like B, Massague J. Cellular distribution of type I and type II receptors for transforming growth factor-beta. J Biol Chem. 1986;261: 9972-9978.
42. Bonewald LF. Regulation and regulatory activities of transforming growth factor beta. Crit Rev Eukaryot Gene Expr. 1999;9:33- 44.
43. Massague J. TGF-beta signal transduction. Annu Rev Biochem. 1998; 67:753-791.
44. Mangasser-Stephan K, Gressner AM. Molecular and functional aspects of latent transforming growth-factor beta binding protein: just a masking protein? Cell Tissue Res. 1999;297:363-370.
45. Hildebrand A, Romaris M, Rasmussen LM, et al. Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta. Biochem J. 1994;302:527- 534.
46. Soo C, Hu F, Zhand X, et al. Differential expression of fibromodulin, a transforming growth factor-beta modulator, in fetal skin development and scarless repair. Am J Pathol. 2000;157:423- 433.
47. Chen RH, Ebner R, Derynck R. Inactivation of the type II receptor reveals two receptor pathways for the diverse TGF-beta activities. Science. 1993;260:1335-1338.
48. Sankar S, Mahooti-Brooks N, Bensen L, et al. Modulation of transforming growth factor beta levels on microvascular endothelial cells during in vitro angiogenesis. J Clin Invest. 1996;97:1436 -1446.
49. Heino J, Heinonen T. Interleukin-1beta prevents the stimulatory effect of transforming growth factor-beta on collagen gene expression in human skin fibroblasts. Biochem J. 1990;271:827- 830.
50. Varga J, Olsen A, Herhal J, et al. Interferon-gamma reverses the stimulation of collagen but not fibronectin gene expression by transforming growth factor-beta in normal human fibroblasts. Eur J Clin Invest. 1990;20:487- 493.
51. Granstein RD, Flotte TJ, Amento EP. Interferons and collagen production. J Invest Dermatol. 1990;95:75S- 80S.
52. Parks WC. Matrix metalloproteinases in repair. Wound Repair Regen. 1999;7:423- 432.
53. Tyagi SC, Kumar S, Katwa L. Differential regulation of extracellular matrix metalloproteinase and tissue inhibitor by heparin and cholesterol in fibroblast cells. J Mol Cell Cardiol. 1997;29:391- 404.